Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a phase III clinical trial to compare the efficacy of docetaxel plus cisplatin versus
5-Fu plus cisplatin in the first line chemotherapy for advanced or metastatic esophageal
squamous carcinoma patients.